Altogether, our findings further support the relevance of CIP2A overexpression as a molecular alteration that leads to p-AKT upregulation, and also indicate that p-AKT plays a predictive role inresponse to doxorubicin in breast cancer patients. This evidence concerns the gene AKT1 and breast carcinoma.